1. Home
  2. ICL vs GRFS Comparison

ICL vs GRFS Comparison

Compare ICL & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICL Group Ltd.

ICL

ICL Group Ltd.

HOLD

Current Price

$5.57

Market Cap

7.2B

Sector

Industrials

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.49

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICL
GRFS
Founded
1968
1940
Country
Israel
Spain
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.2B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
ICL
GRFS
Price
$5.57
$9.49
Analyst Decision
Hold
Hold
Analyst Count
3
2
Target Price
$6.23
$10.15
AVG Volume (30 Days)
1.0M
452.1K
Earning Date
02-25-2026
07-28-2022
Dividend Yield
3.48%
1.50%
EPS Growth
N/A
N/A
EPS
0.29
0.64
Revenue
$7,053,000,000.00
$8,821,017,248.00
Revenue This Year
$5.82
$5.36
Revenue Next Year
$5.42
$5.15
P/E Ratio
$19.37
$18.71
Revenue Growth
1.77
7.31
52 Week Low
$4.85
$6.19
52 Week High
$7.35
$11.14

Technical Indicators

Market Signals
Indicator
ICL
GRFS
Relative Strength Index (RSI) 55.60 63.67
Support Level $4.95 $9.17
Resistance Level $5.84 $9.46
Average True Range (ATR) 0.10 0.19
MACD 0.06 0.04
Stochastic Oscillator 68.54 88.64

Price Performance

Historical Comparison
ICL
GRFS

About ICL ICL Group Ltd.

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates maximum revenue from Brazil followed by, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: